Developing the next generation of CAR-T cell therapies to treat solid cancers

Currus Biologics is developing its proprietary BEAT technology for solid tumors, to enable the use of CAR-T cell therapies for the treatment of solid tumor indications. Currus Biologics’ proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology overcomes many of the challenges presented when treating solid tumours with traditional CAR-T cell therapy, demonstrating CAR-T cell proliferation and persistence, CAR-T cell trafficking to the tumour and immunological memory extending to additional antigens.

Currus Biologics has been spun out of research from Peter MacCallum Cancer Center, a world-leading cancer research and treatment center.

The CUREator program will support critical preclinical studies, preparing this program for the clinical stage.